Sunday, December 1 | 9:30 a.m.-9:40 a.m. | S1-SSNMMI01-4 | Room S405
In this presentation, researchers will discuss gallium-68 (Ga-68) FAPI PET/CT’s utility in breast cancer detection and staging.
Presenter Madina Gabdullina, PhD, of Asfendiyarov Kazakh National Medical University in Kazakhstan will describe how Ga-68 FAPI is superior to F-18 FDG PET/CT in identifying primary breast cancer lesions and leads to upstaging in nearly one-quarter of cases.
The prospective study included 17 women with an average age of 52.5 years who were diagnosed with breast cancer in early 2024. The women underwent both Ga-68 FAPI PET/CT and F-18 FDG PET/CT and had their lesions confirmed histologically.
The researchers identified 20 primary lesions and 43 metastatic lymph nodes in 17 breast cancer patients. They additionally found 10 bone metastases and six liver metastases.
Ga-68 FAPI PET/CT achieved superior sensitivity (100%) and specificity (85.7%) compared with F-18 FDG PET/CT. In addition, Ga-68 FAPI PET/CT identified three primary lesions smaller than 7 mm in size.
The modality also achieved a 100% diagnostic accuracy for lymph node metastasis detection compared with 76.7% for F-18 FDG PET/CT. And for distant metastases, Ga-68 FAPI PET/CT again achieved a diagnostic accuracy of 100% compared to 87.5% for F-18 FDG PET/CT.
Finally, receiver operating characteristic analysis of PET/CT imaging showed a significantly higher area under the curve (AUC) for Ga-68 PET/CT at 0.945 compared to 0.783 for F-18 FDG PET/CT (p < 0.001).
As a result, the study authors concluded that Ga-68 FAPI PET/CT can lead to more precise treatment decisions and may reduce unnecessary interventions, aligning with personalized cancer care, according to the study authors.
Find out more by attending this session.
